8 results for Patent, 2009

  • Oral formulations of Glycyl-2-Methylprolyl-Glutamate.

    Wen, Jingyuan; Thomas, G; Bickerdike, MJ (2009)

    Patent
    The University of Auckland Library

    Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.

    View record details
  • System and method for tracking facial muscle and eye motion for computer graphics animation

    Sagar, Mark; Scott, R (2009)

    Patent
    The University of Auckland Library

    A motion tracking system enables faithful capture of subtle facial and eye motion using a surface electromyography (EMG) detection method to detect muscle movements and an electrooculogram (EOG) detection method to detect eye movements. An embodiment of the motion tracking animation system comprises a plurality of pairs of EOG electrodes adapted to be affixed to the skin surface of the performer at locations adjacent to the performer's eyes. The EOG data comprises electrical signals corresponding to eye movements of a performer during a performance. Programming instructions further provide processing of the EOG data and mapping of processed EOG data onto an animated character. As a result, the animated character will exhibit he same muscle and eye movements as the performer.

    View record details
  • Murine endometriosis modelled by K-ras activation of menstruating endometrium

    Charnock-Jones, D; Print, Cristin; Cheng, C (2009)

    Patent
    The University of Auckland Library

    View record details
  • Substituted pyrimidines and triazines and their use in cancer therapy

    Rewcastle, Gordon; Shepherd, Peter; Chaussade, C; Denny, William; Gamage, Swarnalatha (2009)

    Patent
    The University of Auckland Library

    Provided herein are substituted pyrimidine and triazine derivatives, including bicyclic pyrimidine derivatives, their pharmaceutical compositions, their preparation, and their use as agents or drugs for cancer therapy, either alone or in combination with radiation and/or other anticancer drugs. In one embodiment, the pyrimidine and triazine derivatives are morpholino-pyrimidine, morpholino-triazine, pyridyl-pyrimidine, and pyridyl-triazine derivatives which are selective irreversible inhibitors of the p110α isoform of PI3K.

    View record details
  • Cell marker of melanocyte cell lineage and uses thereof

    Dunbar, PR; Horlacher, O; Feisst, Vaughan (2009)

    Patent
    The University of Auckland Library

    The present invention relates to a novel protein that is a marker of melanocyte cell lineage and cancer cells, and to nucleic acids encoding the novel protein. The invention also relates to treatment of disorders of cells of the melanocyte lineage, and to compositions and methods for treatment of such disorders.

    View record details
  • Pyrazolo[1,5-a]pyridines and their use in cancer therapy

    Kendall, JD; Marshall, Andrew (2009)

    Patent
    The University of Auckland Library

    Phosphoinositide-3-kinases (PI3Ks) are a group of lipid kinases which phosphorylate the 10 3-hydroxyl of phosphoinositides. They are split into three classes (Class I, II and Ill) and play an important role in cellular signalling [Stephens et al., Curr. Opin. Pharmacal. 2005, 5, 357]. The Class I enzymes are further split into Class Ia and lb based on their mechanism of activation; the Class Ia PI3Ks are heterodimeric structures consisting of a catalytic subunit (p11 Oa, p11 013 or p11 0~) in complex with a regulatory p85 subunit, while 15 the class-IB PI3K (p11 Oy) is structurally similar but lacks a reguiatory subunit linking and instead is activated by 13v subunits of heterotrimeric G-proteins [Walker et al,. Moi.Ce/1., 2000, 6, 909]. PI3Ks play a variety of roles in normal tissue physiology [Foukas & Shepherd, Biochem. 20 Soc. Trans., 2004,32, 330; Shepherd,Acta Physiol. Scand,. 2005, 183, 3], with p110a having a specific role in cancer growth, p11 013 in thrombus formation mediated by integrin aul33 [Jackson et al., Nat. Med., 2005, 11, 507], and p11 Oy in inflammation, rheumatoid arthritis [Camps et al., Nat. Med., 2005, 11, 936] and other chronic inflammation states [Barber et al., Nat. Med., 2005, 11, 933]. The PI3K enzymes produce phosphoinositide 25 3,4,5-triphosphate (PIP3) from the corresponding diphosphate (PIP2), thus recruiting AKT (protein kinase B) through its PH domain, to the plasma membrane. Once bound, AKT is phosphorylated and activated by other membrane bound kinases, and is central to a cascade of events that lead to inhibition of apoptosis [Berrie, Exp. Opin. Invest. Drugs, 2001, 10, 1085].

    View record details
  • Transcription Factors

    Bloksberg, LN; Bryant, C; Connett, MB; Emerson, SJ; Frost, MJ; Forster, RLS; Grigor, M; Higgins, C; Lasham, Annette; Lund, ST; Magusin, A; Phillips, J; Puthigae, S; Veerakone, S; Westwood, C; Gause, K; Wood, M; Havukkala, I; Rottmann, WH (2009-03-24)

    Patent
    The University of Auckland Library

    View record details
  • Quinoline derivatives for modulating DNA methylation.

    Brooke, Darby; Phiasivongsa, P; Denny, WA; Gamage, S; Bearss, DJ; Vankayalapati, H; Redkar, SG (2009)

    Patent
    The University of Auckland Library

    (EN)Quinoline derivatives, particularly 4-anilinoquinoline derivatives, are provided. Such quinoline derivatives can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position, for example via selective inhibition of DNA methyltransferase DNMT1. Methods for synthesizing numerous 4-anilinoquinoline derivatives and for modulating DNA methylation are provided. Also provided are methods for formulating and administering these compounds or compositions to treat conditions such as cancer and hematological disorders. (FR)Cette invention concerne des dérivés de quinoline, en particulier des dérivés de 4-anilinoquinoline. Ces dérivés de quinoline peuvent être utilisés dans la modulation de la méthylation de l'ADN, par exemple dans l'inhibition effective de la méthylation de la cytosine en position C-5, par exemple par une inhibition sélective de l'ADN méthyltransférase DNMT1. L'invention concerne par ailleurs des procédés permettant de synthétiser plusieurs dérivés de 4-anilinoquinoline et de moduler la méthylation de l'ADN. L'invention concerne également des procédés permettant de formuler et d'administrer ces composés ou ces compositions pour traiter des pathologies comme le cancer et les troubles hématologiques.

    View record details